News

This marks the second program Ovid has advanced into Phase 2 clinical development this year. Takeda and Ovid formed a global collaboration focused on the clinical development and

Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking,

Under the deal, the partnership will develop new stabilised non-immunogenic modified RNA therapies (mRNA) for respiratory diseases by using Ethris’ SNIM RNA technology. As per terms of the

Duzallo is a combination of 200mg of lesinurad and 300mg of allopurinol and has been approved by the regulator as a once-daily oral therapy for treating the condition

Ligand is also entitled to future milestones and royalties from this antibody. WuXi Biologics was previously contracted by its Chinese partner Harbin Gloria Pharmaceuticals to discover and develop

The two companies will immediately begin working on the program’s first therapeutic candidate, TAK-671, which is intended to treat severe acute pancreatitis. “Takeda’s extensive knowledge and expertise in

According to the drug makers, the PARP inhibitor has been approved as a maintenance treatment for recurrent, epithelial ovarian, fallopian tube or primary peritoneal adult cancer irrespective of

KAF156, which belongs to the class of the imidazolopiperazines, is a next-generation antimalarial compound that holds capability to treat drug-resistant strains of the malaria parasite. The trial was

The study will examine the effectiveness of PLX-R18 as a treatment for Acute Radiation Syndrome (ARS) prior to, and within the first 24 hours of exposure to radiation.